Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Prof Junhua Wu | Tumor Gene Therapy | Excellence in Innovation

Nanjing University | China

Author Profile

Scoups

Orcid ID

JUNHUA WU: PIONEERING RESEARCHER IN BIOMECHANICS AND ONCOLOGY 🔬

EARLY ACADEMIC PURSUITS 🎓

Junhua Wu embarked on his academic journey at Nanjing University (NJU), where he earned both his BSc in Life Sciences (1998–2002) and PhD in Life Sciences (2002–2007). His doctoral studies laid a strong foundation in molecular biology and biomechanics, equipping him with the expertise to make significant contributions to scientific research.

PROFESSIONAL ENDEAVORS 🏅

Following his graduation in June 2007, Junhua Wu remained at Nanjing University as a faculty member. His academic career has progressed steadily:

  • Lecturer (Since September 2007)
  • Associate Professor (Since December 2014)
  • Professor (Since December 2019)

He has received research funding from prestigious sources such as the National Natural Science Foundation of China, Key R&D Plan of Jiangsu Province, Natural Science Foundation of Jiangsu Province, and the Doctoral Program Fund of the Ministry of Education.

As an esteemed scholar, Professor Wu has published over 50 SCI papers in high-impact journals such as Nature Communications and holds 17 national invention patents. He has also contributed to academia through the compilation and translation of scientific monographs. His editorial roles include serving on the boards of Translational Oncology, Biocell, and Discovery Medicine.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR GENE THERAPY🔍

Professor Wu has made groundbreaking contributions in biomechanics, material science, and oncology. His research interests focus on protein hydrogels, tumorigenesis mechanisms, and novel cancer therapies.

1. Creation and Application of Hydrogels 💧

His work on protein hydrogels was a pioneering achievement in the field of biomechanics. He successfully demonstrated the ability to manipulate the mechanical properties of macromaterials by fine-tuning single protein molecules. His study, published in Nature Communications (2018), was a landmark contribution and has been cited 110 times.

His work was recognized in the 100th-anniversary special issue of international macromolecular science and was selected by the China Biomechanics Professional Committee as a key research advancement (2016–2018).

2. Mechanism of Tumorigenesis and Development 🧬

Professor Wu’s contributions to oncology include his exosome theory of sorafenib resistance in hepatocellular carcinoma, published in JECCR (2016). This study has been cited 113 times, influencing subsequent research on drug resistance in various cancers. His findings provided a new understanding of cancer cell communication and treatment resistance.

3. Innovative Cancer Therapies 💊

Professor Wu has developed novel strategies for cancer treatment, leading to over 20 invention patents and more than 30 high-impact SCI publications.

His research on mechanically stable peptide-graphene oxide hybrid hydrogels for drug delivery was highlighted as a Web of Science highly cited paper (Top 1% globally). This work demonstrated precise drug release mechanisms and was recognized for its potential to revolutionize targeted cancer therapy.

His “Trojan Horse” strategy for oncolytic virus delivery represents another major breakthrough. Published in JECCR (2019), this method involves using graphene nanoflakes to enhance viral delivery to tumors, significantly improving therapeutic outcomes.

IMPACT AND INFLUENCE 🌍

Professor Wu’s research has had a profound impact on multiple disciplines, including biomechanics, biomaterials, and oncology. His pioneering studies have inspired global researchers, with scholars from institutions such as the University of Wisconsin-Milwaukee drawing on his ideas for their work in Nature Communications, Science Advances, and PRL.

His cancer therapy innovations have been widely cited and applied by leading oncologists and material scientists. His findings have been positively reviewed and referenced in major scientific publications, solidifying his reputation as a thought leader in the field.

ACADEMIC CITATIONS 📑

Professor Wu’s work has received extensive recognition, accumulating hundreds of citations. Some notable statistics include:

  • 110+ citations for his 2018 Nature Communications paper on protein hydrogels.
  • 113+ citations for his 2016 JECCR paper on exosome-mediated drug resistance.
  • 122+ citations for his 2015 Nanoscale paper on peptide-graphene oxide hybrid hydrogels.

LEGACY AND FUTURE CONTRIBUTIONS 🚀

Professor Junhua Wu’s legacy is defined by his interdisciplinary approach, bridging biomechanics, biomaterials, and cancer therapy. His innovative methodologies continue to shape biomedical engineering and oncology research.

Moving forward, he aims to:

  • Expand the applications of protein hydrogels for regenerative medicine and tissue engineering.
  • Advance tumor microecology studies to develop next-generation immunotherapies.
  • Refine oncolytic virus-based cancer treatments, enhancing their efficacy and clinical applications.

CONCLUSION 🏆

Junhua Wu stands as a pioneering figure in his fields of expertise. His work has redefined our understanding of mechanobiology and cancer treatment, earning him a place among the most influential scientists in modern biomedical research. His dedication to innovation ensures that his impact will continue to resonate for years to come.

NOTABLE PUBLICATIONS 📑

"SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy

  • Authors: P., Wang, Peng , J., Qiu, Jiannan , Y., Fang, Yuan , J., Wu, Junhua , C., Jiang,
  • Journal: Chunping Cell Death and Differentiation
  • Year: 2025

"Thymosin α1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy

  • Authors: K., Liu, Kua , L., Kong, Lingkai , H., Cui, Huawei , C., Jiang, Chunping , J., Wu, Junhua
  • Journal: Cell Reports Medicine
  • Year: 2024

"CuET overcomes regorafenib resistance by inhibiting epithelial-mesenchymal transition through suppression of the ERK pathway in hepatocellular carcinoma

  • Authors: D., Ma, Ding , S., Liu, Shuwen , K., Liu, Kua , J., Wu, Junhua , C., Jiang, Chunping
  • Journal: Translational Oncology
  • Year: 2024

"Toward Practical Applications of Engineered Living Materials with Advanced Fabrication Techniques

  • Authors: C., Lu, Chenjing , Y., Huang, Yaying , J., Cui, Jian , Y., Cao, Yi , S., Yin, Sheng
  • Journal: ACS Synthetic Biology
  • Year: 2024

"Structurally and mechanically tuned macroporous hydrogels for scalable mesenchymal stem cell-extracellular matrix spheroid production

  • Authors: S., Yin, Sheng , H., Wu, Haipeng , Y., Huang, Yaying , W., Wang, Wei , Y., Cao, Yi
  • Journal: Proceedings of the National Academy of Sciences of the United States of America
  • Year: 2024

Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Dr. Sang Yeon Cho | Molecular Cancer Biology | Best Researcher Award

Chungna National University | South Korea

Author Profile 

Scopus

Google Scholar

BIOGRAPHY OF SANG YEON CHO 🌟

EARLY ACADEMIC PURSUITS 🎓

Sang Yeon Cho embarked on his academic journey at Chungnam National University, where he earned his Bachelor's degree in Biochemistry in 2012. He further pursued an M.S. in Medicine, obtaining his MD degree in 2021. Currently, he is completing his Ph.D. in New Drug Discovery and Development, expected to graduate in February 2025. His strong foundation in the sciences has equipped him with the skills necessary for innovative research in the medical field.

PROFESSIONAL ENDEAVORS 🏥

Currently, Dr. Cho serves as the Vice Director of the Metro Neurosurgery Clinic in Daejeon, South Korea, since October 2022. Prior to this role, he was the Vice Director of Hurisarang Hospital from March 2021 to September 2022. His leadership positions reflect his commitment to advancing medical practice and enhancing patient care.

CONTRIBUTIONS AND RESEARCH FOCUS ON MOLECULAR CANCER BIOLOGY 🔬

As the Director of ChoLab since 2018, Dr. Cho has focused on cancer genomics and new drug discovery. His research has investigated the molecular mechanisms underlying cancer, emphasizing drug resistance and therapeutic targets. He has actively contributed to several labs, including the Neuroglia Lab and the Nano Primo Research Center, showcasing his multidisciplinary approach to tackling complex medical challenges.

IMPACT AND INFLUENCE 🌍

Dr. Cho's work has significantly influenced the field of medical genetics and cancer research. His publications in high-impact journals highlight the clinical significance of his findings, making substantial contributions to understanding cancer prognosis and treatment. Through his research, he aims to bridge the gap between laboratory discoveries and clinical applications, improving patient outcomes.

ACADEMIC CITATIONS 📚

His research output includes numerous peer-reviewed articles in respected journals such as BMC Medical Genomics, Scientific Reports, and BMC Cancer, where he explores topics like drug resistance, immunotherapy biomarkers, and cancer prognosis. His findings have garnered attention and citations within the academic community, underscoring the relevance and quality of his work.

LEGACY 🏆

Dr. Cho's dedication to advancing cancer research and patient care has already left a mark on the field. His innovative approach, exemplified by multiple patents related to AI in healthcare and cancer diagnostics, positions him as a forward-thinking researcher poised to shape future developments in medical science.

FUTURE CONTRIBUTIONS 🔮

Looking ahead, Dr. Cho aims to continue his research in cancer treatment and drug discovery, integrating cutting-edge technologies like artificial intelligence to enhance therapeutic strategies. With his expected Ph.D. completion in 2025, he is set to further expand his contributions to the field and inspire the next generation of medical researchers.

NOTABLE PUBLICATIONS 📑

"A method for the observation of the primo vascular system in the thoracic duct of a rat" 

  • Authors: Kim, S., Jung, S.J., Cho, S.Y., Soh, K.-S., Kim, S.
  • Journal: Evidence-based Complementary and Alternative Medicine
  • Year: 2013

"Protocol for the Observation of the Primo Vascular System in the Lymph Vessels of Rabbits" 

  • Authors: Jung, S.J., Cho, S.Y., Bae, K.-H., ... Song, Y.-K., Soh, K.-S.
  • Journal:  Journal of Acupuncture and Meridian Studies
  • Year: 2012

Bin Zhang | Gene Mutation | Best Researcher Award

Prof Bin Zhang | Gene Mutation | Best Researcher Award

Jining Medical University | China

AUTHOR PROFILE

Scopus

Google Scholar

EARLY ACADEMIC PURSUITS

Bin Zhang's journey into the world of medical research began with a solid foundation in biomedical sciences. His early academic pursuits were marked by a dedication to understanding complex biological systems and a passion for contributing to the field of oncology. This academic dedication led him to become a young expert recognized under the prestigious Taishan Mount Scholars program in China.

PROFESSIONAL ENDEAVORS

In 2018, Bin Zhang was appointed as a researcher at the Affiliated Hospital of Jining Medical University. Here, he established the tumor metabolism research group, assuming the role of Principal Investigator. Under his leadership, the group has grown to focus on four key research directions: the regulatory mechanisms of tumor stem cells, the specificity of tumor biomacromolecules and energy metabolism, the regulation of energy metabolism by oncogenic gene mutations, and the screening of potential drugs targeting tumor metabolism.

CONTRIBUTIONS AND RESEARCH FOCUS ON GENE MUTATION

Bin Zhang's research has significantly advanced the understanding of tumor metabolism. His work has been published in esteemed journals such as Cell Reports Medicine, Biomaterials, Oncogene, Journal of Experimental & Clinical Cancer Research, and Stem Cells. These publications highlight his team's investigations into the intricate mechanisms of tumor biology and potential therapeutic targets. The research group delves into how tumor stem cells are regulated, how tumor biomacromolecules function, and how mutations in oncogenes affect energy metabolism, all of which are crucial for developing new cancer treatments.

IMPACT AND INFLUENCE

The impact of Bin Zhang's research is reflected in the high citation rate of his publications, with over 5000 citations to date and an H-Index of 34. His work has not only contributed valuable knowledge to the scientific community but has also influenced ongoing research and development in tumor metabolism. Furthermore, Bin Zhang has successfully secured ten patents, two of which have been transferred, demonstrating the practical applications and commercial potential of his research findings.

ACADEMIC CITES

Bin Zhang is also an active member of the academic community, serving as a reviewer for several high-impact journals including Stem Cells and Development, EBioMedicine, Stem Cell Research & Therapy, Molecular Carcinogenesis, and the Journal of Clinical Laboratory Medicine. His expertise is sought after in evaluating cutting-edge research and ensuring the quality of publications in these journals.

LEGACY AND FUTURE CONTRIBUTIONS

Bin Zhang's legacy in the field of tumor metabolism is marked by his innovative research and commitment to advancing cancer treatment. Currently, he is the principal investigator of two general projects funded by the National Natural Science Foundation of China, two projects funded by Shandong Province, and two projects funded by the Postdoctoral Foundation of China. His ongoing work promises to uncover new insights and develop novel therapies, continuing to push the boundaries of cancer research

NOTABLE PUBLICATIONS

A roadmap from research to clinical testing of mesenchymal stromal cell exosomes in the treatment of psoriasis 2023(7)

IL-13/IL-13RA2 signaling promotes colorectal cancer stem cell tumorigenesis by inducing ubiquitinated degradation of p53 2023(4)

Therapeutic Efficacy of Mesenchymal Stem/Stromal Cell Small Extracellular Vesicles in Alleviating Arthritic Progression by Restoring Macrophage Balance 2023(1)

Engineered EVs with pathogen proteins: promising vaccine alternatives to LNP-mRNA vaccines 2024

Arachidonic acid released by PIK3CA mutant tumor cells triggers malignant transformation of colonic epithelium by inducing chromatin remodeling 2024

Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Prof Richard Lu | Neurodegenerative Diseases | Best Researcher Award

Cincinnati Children's Hospital Medical Center | United States

Author Profile

Scopus

Early Academic Pursuits

Qing Richard Lu embarked on his academic journey with a Bachelor of Science in Biochemistry from Peking Normal University in Beijing, China, which he completed in 1988. Following this, he pursued a Master of Science in Biophysics at Rutgers University, New Jersey, USA, completing his degree in 1993. He continued his studies at Rutgers University, earning a Ph.D. in Biochemistry in 1997 under the mentorship of Dr. Masayori Inouye.

Professional Endeavors

Dr. Lu's professional career began with a postdoctoral fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, from 1997 to 2002. He worked with Dr. Chuck D. Stiles and collaborated with Dr. David Rowitch. In 2002, he joined the UT Southwestern Medical Center as an Assistant Professor in the Department of Developmental Biology, where he held the position of Southwestern Medical Foundation Endowed Scholar in Medical Research. He was promoted to Associate Professor with tenure in 2009 and continued in this role until 2013. In 2013, Dr. Lu joined Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine. He currently holds the position of Professor with tenure in the Department of Pediatrics. Additionally, he serves as the Scientific Director of the Brain Tumor Center and Program Leader of the Brain Tumor Program in the Division of Experimental Hematology and Cancer Biology, Cancer & Blood Diseases Institute.

Contributions and Research Focus on Neurodegenerative Diseases

Dr. Lu's research primarily focuses on the molecular and cellular mechanisms underlying brain tumors. His work is significant in understanding the biology of brain cancer and developing new therapeutic strategies. He has made notable contributions to the field of experimental hematology and cancer biology through his research on brain tumor development, progression, and treatment.

Impact and Influence

Throughout his career, Dr. Lu has influenced the field of pediatric oncology and neurobiology. His research has provided insights into the genetic and biochemical pathways involved in brain tumors, contributing to the development of novel therapeutic approaches. His work has been recognized through various academic appointments and endowed scholarships, reflecting his significant impact on medical research.

Academic Cites

Dr. Lu's work has been widely published in numerous scientific journals, and his research findings are frequently cited by peers in the field. His publications contribute to the broader scientific understanding of brain tumors and their treatment, solidifying his reputation as a leading expert in the field.

Legacy and Future Contributions

As a leading figure in pediatric oncology and neurobiology, Dr. Lu's legacy is marked by his commitment to advancing scientific knowledge and improving patient outcomes. His ongoing research efforts and leadership roles at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati College of Medicine continue to shape the future of brain tumor research and treatment. Dr. Lu’s future contributions are expected to further enhance the understanding and management of brain tumors, paving the way for innovative therapeutic solutions and improved patient care.

Notable Publications